Rangering i aksjer
#38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Aksjekurs
$0.00953895
Sist synkronisert: 2024-05-22
Handel Evgen Pharma plc (EVG)
Pris EVG pris med markedsverdi på B
Markedsverdi av Evgen Pharma plc(EVG)
Markedsverdi: $1.28M
Per August 2026 har Evgen Pharma plc en markedsverdi på $1.28M. Dette gjør Evgen Pharma plc til det 38016th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Evgen Pharma plc fra 2015 til 2026
EVG sammenlignet med topp 5 mest populære stocks
| Pris på EVG |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+424,564,517.03%
|
|
|
|
|
$4.490T
|
+349,660,564.35%
|
|
|
|
|
$4.162T
|
+324,147,665.18%
|
|
|
|
|
$3.676T
|
+286,295,348.85%
|
|
|
|
|
$2.833T
|
+220,623,311.32%
|
